Bicycle Therapeutics (NASDAQ:BCYC) Issues Quarterly Earnings Results, Beats Expectations By $0.25 EPS

Bicycle Therapeutics (NASDAQ:BCYC) posted its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.25, FiscalAI reports. The firm had revenue of $34.06 million for the quarter, compared to analysts’ expectations of $12.22 million. Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%.

Bicycle Therapeutics Trading Down 4.1%

BCYC traded down $0.15 during trading on Friday, hitting $3.67. 231,733 shares of the company’s stock traded hands, compared to its average volume of 423,246. Bicycle Therapeutics has a 12-month low of $3.33 and a 12-month high of $8.48. The company’s 50 day simple moving average is $3.85 and its two-hundred day simple moving average is $4.60. The stock has a market capitalization of $256.52 million, a price-to-earnings ratio of -1.34 and a beta of 1.68.

Analysts Set New Price Targets

A number of brokerages have recently commented on BCYC. Zacks Research cut Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Needham & Company LLC lowered their target price on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Jefferies Financial Group reaffirmed a “buy” rating and set a $10.00 target price on shares of Bicycle Therapeutics in a research note on Thursday. Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, October 2nd. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $13.57.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.